|
 |
Individualize. (Adults) 20 to 80mg given as a single dose. If needed, the same dose can be given 6 to 8 hours later or increased 20 or 40mg up to 600 mg/day, before or after meals.
|
 |
Category C.
|
 |
Cramping, Diarrhea, Constipation, nausea, vomiting, hearing loss, vertigo, dizziness, headache, Blurred Vision, Dehydration, transient Deafness with too rapid I.V.injection, pancreatitis, nocturia, agranulocytosis, leukopenia, thrombocytopenia, Aplastic Anemia, altered liver function test results, hypomagnessmia, weakness, purpura.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | | |
|
